cyclin G1 Inhibitors
Cyclin G1 is a key regulatory protein involved in cell cycle control and cell proliferation. It forms complexes with cyclin-dependent kinases (CDKs) and plays a role in cell cycle progression. Inhibition of cyclin G1 can have significant implications for controlling aberrant cell growth, particularly in cancer therapy. Several chemical inhibitors have been identified to modulate cyclin G1 expression and activity. One class of cyclin G1 inhibitors includes selective CDK4/6 inhibitors like Palbociclib, PD-0332991 (a structural isomer of Palbociclib), and Abemaciclib (a structural isomer of LY2835219). These inhibitors directly target CDK4 and CDK6, which form complexes with cyclin G1. By inhibiting CDK4/6, these chemicals prevent the phosphorylation and subsequent activation of cyclin G1. Consequently, cyclin G1's ability to regulate cell cycle progression is hindered.
Another group of cyclin G1 inhibitors comprises broad-spectrum CDK inhibitors such as Flavopiridol, Dinaciclib, Roscovitine (Seliciclib), SNS-032 (BMS-387032), AT7519, AG-024322, Seliciclib (CYC202), and Dinaciclib (SCH727965). These compounds directly target CDKs involved in cell cycle regulation. By inhibiting various CDKs, they prevent the phosphorylation and activation of cyclin G1, leading to its reduced influence on cell cycle progression. In summary, cyclin G1 inhibitors represent a diverse group of chemicals that primarily target CDKs involved in cell cycle regulation. By inhibiting these CDKs and preventing the phosphorylation of cyclin G1, these inhibitors can modulate cell cycle progression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Inhibition of CDK4/6 can directly impact cyclin G1 by preventing its phosphorylation and subsequent activation. Cyclin G1, when not phosphorylated, may have reduced activity and influence on cell cycle progression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a broad-spectrum CDK inhibitor that can directly target CDKs involved in cell cycle regulation. Inhibition of CDKs by Flavopiridol can lead to decreased phosphorylation and activation of cyclin G1, potentially reducing its ability to modulate the cell cycle. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor that can directly target CDKs involved in cell cycle regulation. Inhibition of CDKs by Dinaciclib can lead to decreased phosphorylation and activation of cyclin G1, potentially reducing its ability to modulate the cell cycle. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, also known as Seliciclib, is a CDK inhibitor that can directly target CDKs involved in cell cycle regulation. Inhibition of CDKs by Roscovitine can lead to decreased phosphorylation and activation of cyclin G1, potentially reducing its ability to modulate the cell cycle. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032, also known as BMS-387032, is a CDK inhibitor that can directly target CDKs involved in cell cycle regulation. Inhibition of CDKs by SNS-032 can lead to decreased phosphorylation and activation of cyclin G1, potentially reducing its ability to modulate the cell cycle. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that can directly target CDKs involved in cell cycle regulation. Inhibition of CDKs by AT7519 can lead to decreased phosphorylation and activation of cyclin G1, potentially reducing its ability to modulate the cell cycle. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
LY2835219, also known as a structural isomer of Abemaciclib, is a CDK inhibitor that can directly impact cyclin G1 by preventing its phosphorylation and subsequent activation. Cyclin G1, when not phosphorylated, may have reduced activity and influence on cell cycle progression. | ||||||